<DOC>
	<DOCNO>NCT03055338</DOCNO>
	<brief_summary>This randomize , placebo-controlled , parallel-group , multi-site , double-blind trial MK-8189 compare placebo , use Risperidone active control . The participant adult subject experience acute episode schizophrenia , accord criterion specify Diagnostic Statistical Manual Mental Disorders , 5th ed . ( DSM-5 ) . This study 7 week duration , 7 site visit participant . The study consist Screening/tapering period ( one week long ) , 4-week treatment period , 14-day follow-up period . The primary objective ass symptom schizophrenia 4 week , assess safety tolerability treatment post-treatment follow-up . The secondary objective ass severity schizophrenia 4 week . The primary hypothesis MK-8189 superior placebo reduce overall symptom schizophrenia assess mean change baseline Positive Negative Syndrome Scale ( PANSS ) total score 4 week treatment .</brief_summary>
	<brief_title>An Active-Controlled Early Phase Study MK-8189 Adults With Schizophrenia ( MK-8189-005 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>18 50 year age Screening Male Female reproductive potential ( e.g. , postmenopausal hysterectomy ) , agree practice abstinence use acceptable contraception Meets diagnostic criterion schizophrenia accord DSM5 criterion , past diagnosis schizophrenia onset first episode &gt; =1 year prior study entry , illness duration &lt; =20 year Is confirm experience acute episode schizophrenia Minimum PANSS score &gt; = 80 Screening Has score &gt; =4 3 5 item ( delusion , conceptual disorganization , hallucinatory behavior , grandiosity , suspiciousness/persecution ) positive subscale PANSS Screening Has CGIS score &gt; = 4 Screening Is able taper psychotropic medication without significant destabilization increase suicidiality Has respond positively antipsychotic medication clozapine prior psychotic episode Has identify responsible external contact person regular contact ( less per week ) participant Is currently involuntary commitment he/she consider danger himself/herself others Is unwilling remain hospitalized duration trial treatment Is currently participate participate interventional clinical research study &lt; =6 month prior Screening , participate one interventional clinical trial research study within 12 month prior Screening Is unwilling allow audio/video tap Mini International Neuropsychiatric Interview Schizophrenia Psychotic Disorders ( MINI ) and/or PANSS interview Screening Baseline Is currently treat benefit medication moderate strong inhibiting induce effect CYP3A and/or CYP2C9 and/or sensitive substrate CYP2B6 Has history malignancy &lt; = 5 year except adequately treat basal cell squamous cell skin cancer situ cervical cancer Has body mass index &lt; 18.5 &gt; 40 kg/mË„2 Has history treatmentresistant schizophrenia Has prolactin laboratory value &gt; = 5 time upper limit normal Screening Has know history clinical evidence clinically significant hepatic , cardiovascular , renal disease , untreated narrowangle glaucoma Has ever diagnose epilepsy seizure disorder beyond one childhood febrile seizure Has serological evidence human immunodeficiency virus ( HIV ) antibody Has history neuroleptic malignant syndrome Has current diagnosis schizophrenia , comorbid diagnosis primarily responsible current symptom functional impairment Has know history borderline personality disorder , antisocial personality disorder , bipolar disorder Has know history traumatic brain injury , Alzheimer 's disease another form dementia Currently meet DSM5 criterion substance abuse alcohol use disorder Is imminent risk selfharm harm others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia , acute episode</keyword>
	<keyword>Schizophrenia Spectrum Other Psychotic Disorders</keyword>
	<keyword>Mental Disorders</keyword>
</DOC>